Several stocks experienced significant price movements based on recent developments. QUALCOMM rose 3.2% following a data center partnership with AWS and positive AI growth outlook. Roivant Sciences surged 18.8% after positive Phase 2 results for its pulmonary hypertension drug. Bloom Energy gained 9.6% after being added to the S&P 500. However, Novartis tumbled 13.9% after its del-desiran drug failed to meet Phase 3 trial expectations for myotonic dystrophy treatment.

Lindus Therapeutics, a drug development company focused on in-licensed assets, has appointed Dr. Gillian Cannon as a non-executive director. Cannon brings over 30 years of biopharmaceutical commercial leadership experience from roles at Merck and Roivant Sciences. She will help shape the company's commercial strategy as it builds its portfolio of clinical-stage assets.

The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.

The generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, BTK inhibitors, and innovative CAR-T cell therapies from major pharmaceutical companies.

Priovant Therapeutics announced enrollment of the first subjects in a Phase 2b/3 clinical trial of brepocitinib for lichen planopilaris (LPP), marking the fourth indication in the drug's late-stage development program. The company expects a potential FDA approval for brepocitinib in dermatomyositis in Q3 2026, with additional Phase 3 data expected in non-infectious uveitis and Phase 3 initiation in cutaneous sarcoidosis in H2 2026.

Priovant Therapeutics announced that its Phase 3 VALOR trial of brepocitinib 30 mg met its primary endpoint for treating dermatomyositis, showing superior efficacy to placebo across multiple measures including muscle strength, skin disease, and corticosteroid reduction. The FDA has granted Priority Review with a PDUFA target action date in Q3 2026. Serious infections were elevated in the treatment group compared to placebo, though they resolved with medical management.

Moderna settled a long-running legal dispute over COVID-19 vaccine technology, paying $2.25 billion to Roivant Sciences' Genevant unit and Arbutus Biopharma—less than the $3 billion expected. While Moderna stock surged 15.99% on the news, analysts suggest it now trades 22% above fair value after a 108% six-month rally. The article identifies 9 biotech stocks trading 27.6% to 64.6% below fair value with potential upside of 31.6% to 251.4%.

Moderna reached a $950 million settlement agreement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving litigation related to its COVID-19 vaccine Spikevax and mRESVIA product. The settlement clears a major legal overhang, allowing the company to focus on future growth. Moderna expects to end 2026 with $4.5-5 billion in cash and aims for breakeven in 2028. The stock surged 8.85% in premarket trading as the settlement value was better than investors' worst-case fears.

Neo Ivy Capital Management initiated a new position in American Healthcare REIT by purchasing 136,925 shares worth approximately $6.44 million. The REIT delivered strong 16.4% same-store NOI growth in Q3, driven by senior housing and integrated senior health campuses segments. Shares have surged 93% over the past year, with management raising full-year guidance.

Immunovant reported Q3 2025 financial results with a net loss of $110.6 million. The company's IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis is fully enrolled with topline data expected in H2 2026. A $550 million financing was completed in December 2025, extending cash runway through potential Graves' disease launch. Development remains on track across multiple indications including GD, MG, CIDP, and SjD.

Pulmovant has completed enrollment in its Phase 2 PHocus clinical trial evaluating mosliciguat for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD) in under 12 months. The company remains on track to report topline results in the second half of 2026. Mosliciguat is a potential first-in-class, once-daily inhaled sGC activator designed to provide targeted pulmonary vasodilation with limited systemic side effects.

Sun Pharmaceutical Industries is reportedly evaluating a potential acquisition of Organon & Co, a U.S.-based women's healthcare company, in what could be India's largest cross-border pharma deal. Sun Pharma has submitted a non-binding all-cash bid with $10-14 billion in acquisition financing arranged. The deal, valued at approximately $10 billion including debt, would significantly strengthen Sun Pharma's presence in the U.S. market and women's health sector, though negotiations remain preliminary with no certainty of completion.